Gossamer Bio (GOSS) Accumulated Expenses (2018 - 2026)

Gossamer Bio's Accumulated Expenses history runs 9 years deep, the most recent figure standing at $19.5 million for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 59.91% year-over-year to $19.5 million; the TTM figure through Mar 2026 stood at $19.5 million (up 59.91% YoY), while the FY2025 annual figure was $15.8 million, up 4.22% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $19.5 million, up from $15.8 million in the prior quarter.
• The five-year high for Accumulated Expenses was $31.5 million in Q3 2022, with the low at $12.2 million in Q1 2025.
• The 5-year median for Accumulated Expenses is $17.0 million (2022), against an average of $18.3 million.
• The sharpest annual moves came in 2022 and 2023: Accumulated Expenses surged 65.17% in 2022, then slumped 45.63% in 2023.
• Gossamer Bio's Accumulated Expenses stood at $20.5 million in 2022, then gained by 29.94% to $26.7 million in 2023, then sank by 43.08% to $15.2 million in 2024, then advanced by 4.22% to $15.8 million in 2025, then rose by 23.51% to $19.5 million in 2026.
• Business Quant data shows GOSS's Accumulated Expenses at $19.5 million in Q1 2026, $15.8 million in Q4 2025, and $19.3 million in Q3 2025.